Early Life and Education
Xie Liangzhi was born in Hunan Province, China, in 1966. He earned a Bachelor's degree in Chemistry and a Master's degree from Dalian University of Technology in 1987 and 1990, respectively. He then pursued further education in the United States, obtaining a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT) in 1996. At MIT, he developed a stoichiometric model to optimize the design of mammalian cell culture medium and the control of the dynamic culture environment.
Career and Achievements
After graduating from MIT, Xie joined Merck & Co. in 1996, where he worked as a research fellow, focusing on viral vaccine development. He was involved in the development and cGMP manufacturing of several US FDA-approved vaccines, including Varivax®, ProQuad®, and Zostavax®. Xie led the cell culture and viral vaccine process development and cGMP clinical production for Merck's adenovirus-based HIV vaccine and contributed to the development of large-scale (2000L) human viral vaccine processes under serum-free conditions.
In 2002, Xie returned to China and founded Sinocelltech Group, specializing in biopharmaceutical drugs. The company focuses on the development and manufacturing of monoclonal antibodies, recombinant proteins, and vaccines. In 2007, he became the President and CEO of Sino Biological Inc.. Under his leadership, Sino Biological Inc. has become a global biotechnology company providing research reagents and CRO services. The company has undertaken many scientific and technological development projects. In June 2020, Sinocelltech was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.
Key Business Strategies
Xie’s success is attributed to his strong technical background, experience in the U.S. biotech industry, and ability to identify opportunities in the growing Chinese biopharmaceutical market. He has focused on building an internationally advanced technology platform to cultivate animal cells on a large scale, establishing a rapid industrial channel for pre-clinical production of genes and proteins. He has also fostered long-term technological outsourcing service partnerships with major pharmaceutical companies.
Philanthropy
Information on specific philanthropy amounts by Xie Liangzhi is unavailable in the search results.
